Is it time to reconsider the treatment paradigm for obese patients with hypertension?
Journal of Human Hypertension, Published online: 02 November 2021; doi:10.1038/s41371-021-00630-4The recent STEP trials reported blood pressure reductions for obese patients treated with semaglutide. We analyzed a cohort of patients attending our hypertension clinic and found that 26% were severely or morbidly obese and morbidly obese patients frequently had resistant hypertension (41%). We suggest semaglutide may be an effective anti-hypertensive agent for obese patients with resistant hypertension and this hypothesis should be assessed in randomized clinical trials.
Source: Journal of Human Hypertension - Category: Cardiology Authors: Cormac Kennedy Osama Ali Richard Farnan Mary Hall John Stinson Patricia O ’Connor Martina Hennessy Michael Barry Source Type: research
More News: Cardiology | Clinical Trials | Eating Disorders & Weight Management | Hypertension | Obesity